• Journal of Pharmaceutical Investigation
• /
• v.5 no.1
• /
• pp.1-9
• /
• 1975

이 문헌종설(文獻綜設)은 1974년도(年度) 하기(下記) 학술지(學術誌)에 게재된 생물약제학(生物藥劑學)에 관한 보문중 (報文中) Pharmacokinetics에 관(關)한 보문(報文)만을 개설(槪設)한 것이다. Journal of Pharmacokinetics and Biopharmaceutics ($No.1{\sim}No.6$) Journal of Pharmaceutical Sciences ($No.1{\sim}No.12$) Journal of Pharmacology and Pharmacy ($No.7{\sim}No.12$ and supplment) Durg & Cosmetic Industry ($No.7{\sim}No.12$) Chemical and Pharmaceutical Bulletin ($No.7{\sim}No.12$) American Journal of Hospital Pharmacy ($No.7{\sim}No.12$) 약학잡지(藥學雜誌) (제7호${\sim}$제12호)(第7號${\sim}$第12號) 무전연구소보(武田硏究所報) (제1호${\sim}$제4호)(第1號{\sim}$第4號)

• Journal of Pharmaceutical Investigation
• /
• v.14 no.4
• /
• pp.156-160
• /
• 1984

The pharmacokinetics of acetaminophen administered intravenously(20mg/kg) was investigated in the rabbits of carbon tetrachloride induced hepatic failure. The blood level, the total AUC and the biological half life of acetaminophen were increased significantly in hepatic failure rabbits compared with those of normal rabbits. The urinary excretion and the overall elimination rate of acetaminophen were decreased significantly in hepatic failure rabbits. There was significant relationship between GOT value and AUC or biological half life of acetaminophen.

• Journal of Pharmaceutical Investigation
• /
• v.39 no.5
• /
• pp.373-379
• /
• 2009

This study was conducted to develop a pharmacokinetic-pharmacodynamic (PK/PD) model of a direct thrombin inhibitor, argatroban to predict the concentration-effect profiles in rats. Argatroban was i.v. injected to rats at 0. 2, 0.8 and 3.2 mg/kg doses (n = 4-5 per dose), and plasma drug levels were determined by a validated LC/MS/MS assay. The pharmacokinetics of argatroban was linear over the i.v. dose range studied. The thrombin time (TT) and the activated partial thromboplastin time (aPTT) were measured in rat plasma and they were found to linearly increase with increasing the dose. A 2-compartment pharmacokinetic model linked with an indirect response pharmacodynamic model was successfully utilized to evaluate the drug concentration-response relationship.

• Archives of Pharmacal Research
• /
• v.13 no.2
• /
• pp.147-150
• /
• 1990

Methotrexate (MTX)-poly-L-lysine (PLL) conjugate was relatively stable in phosphate buffer of pH 7.4 and in plasma. However, liver homogenate accelerated the release of MTX from the conjugate. Pharmacokinetics and tissue distribution of MTX were compared after intramuscular injection of MTX (treatment I) and MTX-PLL conjugate (treatment II), 10 mg/kg as free MTX to rabbits. The peak concentration of MTX in treatment II were significantly lower than those in treatment I. The amount of MTX excreted in 24-hr urine was significantly reduced in treatment II and it suggested that MTX be more metabolized in treatment II than in treatment I. The amounts of MTX remaining in each organ after 24-hr of intramuscular injection were not significantly different in both treatments.

• YAKHAK HOEJI
• /
• v.33 no.6
• /
• pp.345-349
• /
• 1989

This paper was attempted to investigate effect of angiotensin inhibitor (loading dose 25, 50, $100{\mu}g/kg$ and maintenance dose 12.5, 25, $50{\mu}g/kg/hr$) on the pharmacokinetics of furosemide (5 mg/kg i.v) in rabbit. The plasma concentrations of furosemide increased by angiotensin inhibitor and the relative bioavailability of furosemide increased from 118.1% to 193.2% by the inhibitor. The protein binding of furosemide decreased by angiotensin inhibitor in bovine serum albumin ($2.17\;{\times}\;10^{-4}M$) by equilibrium dialysis method. Consequently, dosage regimen of furosemide might be adjusted carefully when furosemide is administered with angiotensin inhibitor.

• YAKHAK HOEJI
• /
• v.34 no.1
• /
• pp.40-46
• /
• 1990

Pharmacokinetic studies on praziquantel in rabbits were performed in this paper. The pharmacologically active parent drug was separated from the pharmacologically inactive metabolites by HPLC method. The pharmacokinetic parameters of parent drug were obtained. In vitro partition to blood cells of praziquantel was measured. The mean value (n = 3) of partition to blood cells was 44% at concentrations between $1\;{\mu}g/ml$ and $40\;{\mu}g/ml$. Therefore, the relatively high partition to blood cells should be considered in further pharmacokinetic studies on praziquantel.

• YAKHAK HOEJI
• /
• v.46 no.4
• /
• pp.265-269
• /
• 2002

The purpose of this study was to report the pharmacokinetic changes of cyclosporine after oral administration of cyclosporine, 10 mg/kg, in rabbits coadministered or pretreated twice per day for 3 days with nimodipine, dose of 5 mg/kg. The area under the plasma concentration-time curve (AUC) of cyclosporine was significantly higher in rabbits pretreated with nimodipine than that in control rabbits (p＜0.01), showing about 149％ increased relative bioavailability. The peak plasma concentration (C$_{max}$), elimination half-life (t$_{1}$2/) and MRT of cyclosporine were increased significantly (p＜0.05) in rabbits pretreated with nimodipine compared with those in control rabbits. This findings could be due to significant reduction of elimination rate constant and total body clearance by pretreated with nimodipine. The effects of nimodipine on the pharmacokinetics of oral cyclosporine were more considerable in rabbits pretreated with nimodipine compared with those in control rabbits. The results suggest that the dosage of cyclosporine should be adjusted when the drug would be coadministered chronically with nimodipine in a clinical situation.n.

• YAKHAK HOEJI
• /
• v.27 no.2
• /
• pp.149-154
• /
• 1983

The effect of hydrochlorothiazide on the pharmacokinetics of carteolol in rabbits was studied. Animals were divided into two groups (group I and group II). Group I received carteolol (12mg/kg) and group II received carteolol (12mg/kg) with hydrochlorothiazide (20mg/kg) orally. The carteolol concentration in serum was measured by spectrofluorometric method and its pharmacokinetic parameter values were calculated. The serum concentration of carteolol in group II was significantly increased when compared with those in group I at 10min (p<0.01), and at 30min (p<0.05) after p. o. administration. In addition, the absorption rate constant of carteolol in group II was slightly increased and Tmax of carteolol in group II was significantly shortened (p<0.05) and Cmax of carteolol in group II was significantly increased (p<0.02) when compared with those in group I. But elimination rate constant and biological half-life of carteolol were similar in both groups.

• Bulletin of the Korean Chemical Society
• /
• v.34 no.5
• /
• pp.1559-1562
• /
• 2013

• YAKHAK HOEJI
• /
• v.47 no.6
• /
• pp.444-459
• /
• 2003

Ethosuximide is an oral anticonvulsantic agent used in the first choice anti-absence seizure drug. The purpose of this study was to assess the pharmacokinetic profile of the ethosuximide in healthy Korean volunteers and to develop the efficient assay method of ethosuximide in human plasma. The pharmacokinetics of ethosuximide administered orally was evaluated after a dose of 500 mg. Ethosuximide was assayed from plasma by a specific HPLC method reading absorbance at 195 nm. AUC was 1222$\pm$160 $\mu\textrm{g}$/$m\ell$$.$hr, $C_{max}$ 14.2l$\pm$1.74 $\mu\textrm{g}$/$m\ell$, $T_{max}$ 1.06$\pm$0.62 hr and half-life 77.83$\pm$12.46 hr. The half-life in Korean was longer than, in Caucasian (53∼56 hr).).).